Inspire misses CF endpoint

Inspire Pharmaceuticals Inc. (NASDAQ:ISPH) fell $4.93 (59%) to $3.47 on Monday after denufosol missed the primary endpoint in the Phase III TIGER-2 trial to treat cystic fibrosis. The second-generation P2Y2 receptor agonist did not significantly improve forced expiratory volume in one second (FEV1) at 48 weeks vs. placebo (40 vs. 32 mL, p=0.742). The double-blind, international trial enrolled 466 patients. Based on TIGER-2's results, Inspire said it will recommend that the open-label DEFY extension trial be stopped. The company said it plans to provide more information about the program by mid-February. ...